These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 29129759)

  • 1. Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists.
    Holdsworth G; Greenslade K; Jose J; Stencel Z; Kirby H; Moore A; Ke HZ; Robinson MK
    Bone; 2018 Feb; 107():93-103. PubMed ID: 29129759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dkk1 KO Mice Treated with Sclerostin Antibody Have Additional Increases in Bone Volume.
    Morse A; Cheng TL; Schindeler A; McDonald MM; Mohanty ST; Kneissel M; Kramer I; Little DG
    Calcif Tissue Int; 2018 Sep; 103(3):298-310. PubMed ID: 29845410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats.
    Stolina M; Dwyer D; Niu QT; Villasenor KS; Kurimoto P; Grisanti M; Han CY; Liu M; Li X; Ominsky MS; Ke HZ; Kostenuik PJ
    Bone; 2014 Oct; 67():305-13. PubMed ID: 25093263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of Sost/Sclerostin and Dickkopf-1 Augment Intervertebral Disc Structure in Mice.
    Kroon T; Bhadouria N; Niziolek P; Edwards D; Choi R; Clinkenbeard EL; Robling A; Holguin N
    J Bone Miner Res; 2022 Jun; 37(6):1156-1169. PubMed ID: 35278242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sclerostin Antibody Augments the Anabolic Bone Formation Response in a Mouse Model of Mechanical Tibial Loading.
    Morse A; Schindeler A; McDonald MM; Kneissel M; Kramer I; Little DG
    J Bone Miner Res; 2018 Mar; 33(3):486-498. PubMed ID: 29090474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential time-dependent transcriptional changes in the osteoblast lineage in cortical bone associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Hu R; Pacheco E; Locher K; Pyrah I; Ominsky MS; Boyce RW
    Bone Rep; 2018 Jun; 8():95-103. PubMed ID: 29955627
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional Profiling of Laser Capture Microdissected Subpopulations of the Osteoblast Lineage Provides Insight Into the Early Response to Sclerostin Antibody in Rats.
    Nioi P; Taylor S; Hu R; Pacheco E; He YD; Hamadeh H; Paszty C; Pyrah I; Ominsky MS; Boyce RW
    J Bone Miner Res; 2015 Aug; 30(8):1457-67. PubMed ID: 25678055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanically Driven Counter-Regulation of Cortical Bone Formation in Response to Sclerostin-Neutralizing Antibodies.
    Gerbaix M; Ammann P; Ferrari S
    J Bone Miner Res; 2021 Feb; 36(2):385-399. PubMed ID: 33049076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reactivation of Bone Lining Cells are Attenuated Over Repeated Anti-sclerostin Antibody Administration.
    Hong AR; Yang JY; Lee JY; Suh J; Lee YS; Kim JE; Kim SW
    Calcif Tissue Int; 2022 Nov; 111(5):495-505. PubMed ID: 35925416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Inhibition of the Wnt Inhibitors DKK1 and Sclerostin Promotes Fracture Healing and Increases the Density and Strength of Uninjured Bone: An Experimental Study in Nonhuman Primates.
    Florio M; Kostenuik PJ; Stolina M; Asuncion FJ; Grisanti M; Ke HZ; Ominsky MS
    J Bone Joint Surg Am; 2023 Aug; 105(15):1145-1155. PubMed ID: 37159527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sclerostin Antibody Reverses Bone Loss by Increasing Bone Formation and Decreasing Bone Resorption in a Rat Model of Male Osteoporosis.
    Li X; Ominsky MS; Villasenor KS; Niu QT; Asuncion FJ; Xia X; Grisanti M; Wronski TJ; Simonet WS; Ke HZ
    Endocrinology; 2018 Jan; 159(1):260-271. PubMed ID: 29069393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sclerostin neutralization unleashes the osteoanabolic effects of Dkk1 inhibition.
    Witcher PC; Miner SE; Horan DJ; Bullock WA; Lim KE; Kang KS; Adaniya AL; Ross RD; Loots GG; Robling AG
    JCI Insight; 2018 Jun; 3(11):. PubMed ID: 29875318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of glucocorticoid treatment on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship with bone turnover.
    Gifre L; Ruiz-Gaspà S; Monegal A; Nomdedeu B; Filella X; Guañabens N; Peris P
    Bone; 2013 Nov; 57(1):272-6. PubMed ID: 23981659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin antibody promotes bone formation through the Wnt/β-catenin signaling pathway in femoral trochlear after patellar instability.
    Xu C; Ji G; Chen X; Yan L; Liang T; Liu J; Wang F
    Connect Tissue Res; 2023 Mar; 64(2):148-160. PubMed ID: 36379907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of sclerostin antibodies in animal models of osteoporosis.
    Ominsky MS; Boyce RW; Li X; Ke HZ
    Bone; 2017 Mar; 96():63-75. PubMed ID: 27789417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-dependent cellular and transcriptional changes in the osteoblast lineage associated with sclerostin antibody treatment in ovariectomized rats.
    Taylor S; Ominsky MS; Hu R; Pacheco E; He YD; Brown DL; Aguirre JI; Wronski TJ; Buntich S; Afshari CA; Pyrah I; Nioi P; Boyce RW
    Bone; 2016 Mar; 84():148-159. PubMed ID: 26721737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rictor is required for optimal bone accrual in response to anti-sclerostin therapy in the mouse.
    Sun W; Shi Y; Lee WC; Lee SY; Long F
    Bone; 2016 Apr; 85():1-8. PubMed ID: 26780446
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sclerostin Antibody Treatment Improves the Bone Phenotype of Crtap(-/-) Mice, a Model of Recessive Osteogenesis Imperfecta.
    Grafe I; Alexander S; Yang T; Lietman C; Homan EP; Munivez E; Chen Y; Jiang MM; Bertin T; Dawson B; Asuncion F; Ke HZ; Ominsky MS; Lee B
    J Bone Miner Res; 2016 May; 31(5):1030-40. PubMed ID: 26716893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tissue-level mechanisms responsible for the increase in bone formation and bone volume by sclerostin antibody.
    Ominsky MS; Niu QT; Li C; Li X; Ke HZ
    J Bone Miner Res; 2014 Jun; 29(6):1424-30. PubMed ID: 24967455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination sclerostin antibody and zoledronic acid treatment outperforms either treatment alone in a mouse model of osteogenesis imperfecta.
    Little DG; Peacock L; Mikulec K; Kneissel M; Kramer I; Cheng TL; Schindeler A; Munns C
    Bone; 2017 Aug; 101():96-103. PubMed ID: 28461254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.